drugset / Trial / NCT01681199

Fluvastatin AmelIorates aTHerosclerosis Study

NCT01681199

Phase 4 Unknown 140 enrolled Beijing Anzhen Hospital Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The study is designed to assess the effect of statin on atherosclesrosis progression as well as to explore its potential mechanism besides lipid modifying , such as effect on inflammation and vascular calcification.

Timeline

Start
2012-07
Primary completion
2014-04
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluvastatin Other / unclassified 80 mg